Glenmark Pharmaceuticals has reported results for fourth quarter ended March 31, 2012
The company has posted a rise of 124.97% in its net profit at Rs 148.23 crore for the quarter ended March 31, 2012 as compared to Rs 65.89 crore for the same quarter in the previous year. Total income has increased by 31.67% at Rs 502.15 crore for quarter under review as compared Rs 381.38 crore for the quarter ended March 31, 2011.
On the consolidated basis, the company has posted a rise of 32.55% in its net profit at Rs 150.35 crore for the quarter ended March 31, 2012 as compared to Rs 113.43 crore for the same quarter in the previous year. Total income has increased by 20.62% at Rs 1068.54 crore for quarter under review as compared to Rs 885.90 crore for the quarter ended March 31, 2011.
For the full year ended March 31, 2012, the company has posted a rise of 25.04% in its net profit at Rs 265.29 crore for the year ended March 31, 2012 as compared to Rs 212.17 crore for the same period in the previous year. Total income has increased by 31.19% at Rs 1619.76 crore for year under review as compared to Rs 1234.69 crore for the period ended March 31, 2011.
On the consolidated basis, the company has posted a marginal rise of 1.58% in its net profit at Rs 460.34 crore for the year ended March 31, 2012 as compared to Rs 453.20 crore for the same period in the previous year. Total income has increased by 30.56% at Rs 4038.81 crore for year under review as compared to Rs 3093.48 crore for the period ended March 31, 2011.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |